127 related articles for article (PubMed ID: 38458809)
1. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.
Hudson EM; Noutch S; Webster J; Brown SR; Boele FW; Al-Salihi O; Baines H; Bulbeck H; Currie S; Fernandez S; Hughes J; Lilley J; Smith A; Parbutt C; Slevin F; Short S; Sebag-Montefiore D; Murray L
BMJ Open; 2024 Mar; 14(3):e078926. PubMed ID: 38458809
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
Bhaskaran D; Savage J; Patel A; Collinson F; Mant R; Boele F; Brazil L; Meade S; Buckle P; Lax S; Billingham L; Short SC
BMC Cancer; 2024 Jan; 24(1):83. PubMed ID: 38225549
[TBL] [Abstract][Full Text] [Related]
3. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
[TBL] [Abstract][Full Text] [Related]
5. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.
Li J; Zhao Z; Du G; Dai T; Zhen X; Cai H; Liao D; Xiang M; Wen Y; Geng L; Yang X; Feng G; Zhang Y; Bai J; Liu L; Du X
Medicine (Baltimore); 2019 Jun; 98(26):e16176. PubMed ID: 31261551
[TBL] [Abstract][Full Text] [Related]
8. ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Pepper NB; Eich HT; Müther M; Oertel M; Rehn S; Spille DC; Stummer W
Radiat Oncol; 2024 Jan; 19(1):11. PubMed ID: 38254201
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS; Forde PM; Hughes B; Sun Z; Brown C; Ramalingam S; Cook A; Lesterhuis WJ; Yip S; O'Byrne K; Pavlakis N; Brahmer J; Anagnostou V; Ford K; Fitzpatrick K; Bricker A; Cummins MM; Stockler M; Nowak AK;
BMJ Open; 2022 Jan; 12(1):e057663. PubMed ID: 35078853
[TBL] [Abstract][Full Text] [Related]
11. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
[TBL] [Abstract][Full Text] [Related]
12. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II).
PelvEx Collaborative
BJS Open; 2021 May; 5(3):. PubMed ID: 34089596
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial.
Xie J; Xu F; Zhao Y; Cai G; Lin X; Zhu Q; Lin Q; Yao Y; Xu C; Cai R; Wang S; Tang X; Chen C; Zheng S; Chen M; Chen M; Qian X; Shen C; Li J; Xu H; Xu F; Han Y; Li M; Ou D; Shen KW; Qi WX; Cao L; Huang X; Chen J
BMJ Open; 2022 Sep; 12(9):e062034. PubMed ID: 36581983
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
17. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
20. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
